SpyGlass Pharma Inc (SGP)
SpyGlass Pharma Inc. is a healthcare company focused on ophthalmic drug delivery for patients with chronic eye diseases. The company is developing the Bimatoprost Drug Pad-IOL System, or BIM-IOL System, which uses proprietary drug pads attached to an intraocular lens and is designed for implantation during routine cataract surgery to help lower elevated intraocular pressure in patients. SpyGlass Pharma is also working on a separate ring-shaped, sustained-release implant that uses bimatoprost without an IOL component. The company was founded in 2019, was previously known as SpyGlass Ophthalmics, Inc., and adopted its current name in April 2021. It is based in Aliso Viejo, California, and its common stock trades on NASDAQ under the symbol SGP.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SGP
|
$13.65
|
-34.7% Downside
|
Overvalued
|
$45
|
115.2% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-15.6x
|
2.8x
|
—
|
669.3 M
|
449.7 M
|
0.2%
|
19.4%
|
48.4
|
—
|
87.7%
|
